Janney Montgomery Scott LLC Sells 163,437 Shares of Boston Scientific Corporation $BSX

Janney Montgomery Scott LLC decreased its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 53.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 139,555 shares of the medical equipment provider’s stock after selling 163,437 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Boston Scientific were worth $8,757,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Louisbourg Investments Inc. boosted its holdings in Boston Scientific by 968.9% in the first quarter. Louisbourg Investments Inc. now owns 84,087 shares of the medical equipment provider’s stock worth $5,276,000 after purchasing an additional 76,220 shares in the last quarter. Caldwell Trust Co raised its holdings in Boston Scientific by 45.3% during the first quarter. Caldwell Trust Co now owns 9,940 shares of the medical equipment provider’s stock valued at $624,000 after buying an additional 3,101 shares in the last quarter. Cornerstone Wealth Group LLC lifted its position in shares of Boston Scientific by 1,323.9% in the first quarter. Cornerstone Wealth Group LLC now owns 64,233 shares of the medical equipment provider’s stock worth $3,823,000 after buying an additional 59,722 shares during the last quarter. Border to Coast Pensions Partnership Ltd bought a new stake in shares of Boston Scientific during the 1st quarter worth about $24,341,000. Finally, Pictet Asset Management Holding SA boosted its stake in shares of Boston Scientific by 19.1% during the 1st quarter. Pictet Asset Management Holding SA now owns 5,120,057 shares of the medical equipment provider’s stock worth $321,301,000 after acquiring an additional 820,284 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig acquired 3,580 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The stock was bought at an average cost of $56.68 per share, with a total value of $202,914.40. Following the completion of the transaction, the director owned 25,359 shares of the company’s stock, valued at $1,437,348.12. The trade was a 16.44% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Cheryl Pegus acquired 1,770 shares of the stock in a transaction dated Wednesday, May 20th. The stock was bought at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the purchase, the director owned 1,770 shares of the company’s stock, valued at $99,987.30. The trade was a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 9,800 shares of company stock worth $554,012 over the last three months. 0.34% of the stock is currently owned by insiders.

Boston Scientific Trading Down 0.1%

Boston Scientific stock opened at $45.09 on Friday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. The business’s 50-day simple moving average is $50.99 and its 200-day simple moving average is $69.43. The firm has a market capitalization of $67.01 billion, a PE ratio of 18.86, a PEG ratio of 0.86 and a beta of 0.58. Boston Scientific Corporation has a 52 week low of $42.25 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.01. The firm had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities research analysts forecast that Boston Scientific Corporation will post 3.36 earnings per share for the current year.

Boston Scientific declared that its board has initiated a stock repurchase program on Monday, May 18th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on BSX. Zacks Research downgraded Boston Scientific from a “hold” rating to a “strong sell” rating in a research note on Friday, June 5th. Robert W. Baird set a $70.00 target price on Boston Scientific in a research report on Thursday, May 28th. Leerink Partners lowered their price target on Boston Scientific from $87.00 to $74.00 and set an “outperform” rating on the stock in a report on Thursday, May 28th. Citigroup dropped their price target on shares of Boston Scientific from $87.00 to $70.00 and set a “buy” rating on the stock in a research report on Thursday, May 28th. Finally, Mizuho reduced their price objective on shares of Boston Scientific from $115.00 to $90.00 and set an “outperform” rating for the company in a research note on Monday, April 13th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $83.36.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.